BPC-157 + TB-500: The Recovery Stack Guide
The two most widely combined recovery peptides, how their mechanisms complement each other, what providers typically prescribe, and what the research actually supports. An honest look at the “Wolverine stack.”
If you spend any time in the peptide therapy space, you will encounter the “Wolverine stack” — BPC-157 and TB-500 combined in a recovery protocol. The name is borrowed from a comic book character who heals from anything. The comparison oversells the reality, but the combination itself has a genuine mechanistic rationale and is the most commonly prescribed multi-peptide protocol in regenerative medicine practice.
Both peptides received favorable PCAC recommendations in July 2026, each passing 8-6 with one abstention. Both are in Category 1 under the FDA’s enforcement framework. And both are available through licensed providers and 503A compounding pharmacies.
Here is what the combination is, what the evidence supports, where it falls short, and how providers approach it in clinical practice.
How They Work: Two Different Mechanisms
The rationale for combining BPC-157 and TB-500 is not “more peptide = more healing.” It is that they operate through different biological pathways, and the combination covers more recovery territory than either one alone.
Primary mechanism: Promotes angiogenesis (new blood vessel formation), bringing oxygen and nutrients to damaged tissue. Acts locally at the site of injury.
Research profile: 300+ preclinical studies. Strongest evidence in gut healing, tendon and ligament repair, musculoskeletal recovery, and neuroprotection. One small retrospective case series (12 patients) reported relief in chronic knee pain.
Delivery: Subcutaneous injection near the injury site, or oral for GI applications. Read the full BPC-157 profile.
Primary mechanism: Regulates actin, a protein involved in cell migration and tissue remodeling. Promotes systemic anti-inflammatory and wound healing effects. Acts throughout the body, not just locally.
Research profile: Based on Thymosin β4 research. Two Nature publications established cardiac repair models. A Phase 2b trial in acute myocardial infarction completed enrollment. Phase 1 IV study reported no serious adverse events at high doses.
Delivery: Subcutaneous injection, typically not site-specific. Systemic distribution.
BPC-157 works locally. It drives blood vessel formation at the injury site, accelerating the delivery of repair resources to the specific area that needs healing. Think of it as building new supply routes directly to the damage.
TB-500 works systemically. It modulates inflammation body-wide and promotes cell migration to damaged tissue. It does not just heal one spot — it shifts the body’s overall recovery environment.
Together: The theory is that BPC-157 concentrates repair at the target site while TB-500 creates favorable systemic conditions for healing. Local infrastructure plus systemic environment. That is the mechanistic rationale. It is plausible and well-reasoned. It is not, however, proven in controlled human trials.
What Providers Typically Prescribe
The following reflects commonly referenced physician-directed protocols. These are not dosing instructions — your provider determines your specific protocol based on your clinical situation, body weight, injury type, and bloodwork. See our prescribing guide for how to start the process.
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| Typical Dose | 250–500 mcg per injection | 2–2.5 mg per injection |
| Frequency | Once or twice daily | Twice weekly (loading), once weekly (maintenance) |
| Administration | Subcutaneous, often near injury site | Subcutaneous, any site (systemic) |
| Loading Phase | Full dose from day one | 4–6 weeks at 2x/week |
| Maintenance | Same dose throughout | Reduce to 1x/week after loading |
| Cycle Length | 4–8 weeks | 4–8 weeks |
| Break Between Cycles | 2–4 weeks | 2–4 weeks |
| Typical Monthly Cost | $150–$350 | $150–$300 |
Some compounding pharmacies offer pre-blended “Wolverine” vials containing both peptides in a single reconstitution, simplifying the protocol to one daily injection. Whether to use separate vials or a blend is a conversation with your provider and pharmacy.
No published controlled study has evaluated BPC-157 and TB-500 as a combination in humans. The individual peptides each have preclinical research bases (primarily animal models), and the combination rationale is based on complementary mechanisms. The reported synergy draws from clinical practice experience and community observation, not randomized trials. This is important context for setting realistic expectations. A provider who represents the stack as clinically proven is overstating the evidence.
Common Use Cases
Tendon and Ligament Injuries
The most common application. BPC-157’s preclinical literature is strongest in tendon and ligament repair models, and TB-500’s cell migration effects are relevant to the slow-healing, low-vascularity nature of connective tissue. Rotator cuff issues, Achilles tendinopathy, tennis elbow, and knee ligament injuries are the conditions most frequently cited by providers using this stack.
Post-Surgical Recovery
Some providers prescribe the stack before and after surgical procedures to support wound healing and reduce recovery time. The angiogenic effects of BPC-157 and the anti-inflammatory properties of TB-500 are the relevant mechanisms. This use requires coordination with the surgical team.
Chronic Musculoskeletal Pain
For injuries that have not responded to physical therapy, NSAIDs, or other conservative treatment. The combination targets both the local tissue damage (BPC-157) and the systemic inflammatory environment that can perpetuate chronic pain cycles (TB-500).
Athletic Recovery
Used by recreational athletes and fitness enthusiasts for recovery from training-related soft tissue stress. Note that both peptides are prohibited by WADA — tested athletes cannot use them regardless of how they are sourced. See our BPC-157 legal status guide for the full WADA discussion.
What to Know Before Starting
Bloodwork First
Providers typically require baseline labs before prescribing any peptide protocol. For a recovery stack, the standard panels include CMP, CBC, inflammatory markers (CRP, ESR), and IGF-1. These serve both as safety baselines and as measurable markers to track whether the protocol is having an effect. See our bloodwork guide for details on each test.
Injection Technique Matters
BPC-157 is typically injected subcutaneously near the injury site. TB-500 is injected subcutaneously at any convenient site (abdomen, thigh) since it distributes systemically. Proper reconstitution technique, sterile practices, and injection-site rotation all affect both safety and efficacy. If you are new to self-injection, ask your provider for guided instruction — this is a reasonable request.
Storage
Lyophilized (unreconstituted) peptides should be stored at room temperature or refrigerated. Once reconstituted with bacteriostatic water, vials must be refrigerated at 2–8°C and used within the beyond-use dating on the label (typically 28–30 days). Do not freeze reconstituted peptides.
Realistic Expectations
Provider reports and community experience suggest noticeable effects in 2–4 weeks for BPC-157 and 4–6 weeks for TB-500. A full cycle typically runs 6–8 weeks. These are not instant fixes. Peptide therapy supplements your body’s own repair processes — it does not replace the need for rest, appropriate rehabilitation, and addressing the underlying cause of the injury.
Both BPC-157 and TB-500 are in Category 1 under the FDA’s interim enforcement framework. Both received 8-6 PCAC recommendations in July 2026. Formal 503A Bulks List placement is pending rulemaking expected in 2027. Some providers are prescribing them now through licensed 503A compounding pharmacies. See our step-by-step prescribing guide to get started.
Frequently Asked Questions
Sources
Mechanistic and preclinical data drawn from the BPC-157 research literature (300+ published studies, primarily animal models; one small retrospective case series in chronic knee pain). TB-500 references based on Thymosin β4 publications including Bock-Marquette et al. (Nature, 2004) and Smart et al. (Nature, 2007), plus the Phase 2b acute MI trial (NCT05984134). Protocol ranges compiled from publicly available physician-directed protocols and compounding pharmacy pricing. PCAC vote tallies from the July 23–24, 2026 meeting record (docket FDA-2025-N-6895).